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Abstract
Background: The 3-hydroxy-3-methylglutaryl CoA reductase inhibitors (also called statins) exert proven beneficial effects on
cardiovascular diseases. Recent data suggest a protective role for Transforming Growth Factor-b (TGF-b) in atherosclerosis
by regulating the balance between inflammation and extracellular matrix accumulation. However, there are no studies
about the effect of statins on TGF-b/Smad pathway in atherosclerosis and vascular cells.
Methodology: In cultured vascular smooth muscle cells (VSMCs) statins enhanced Smad pathway activation caused by TGF-
b. In addition, statins upregulated TGF-b receptor type II (TRII), and increased TGF-b synthesis and TGF-b/Smad-dependent
actions. In this sense, statins, through Smad activation, render VSMCs more susceptible to TGF-b induced apoptosis and
increased TGF-b-mediated ECM production. It is well documented that high doses of statins induce apoptosis in cultured
VSMC in the presence of serum; however the precise mechanism of this effect remains to be elucidated. We have found that
statins-induced apoptosis was mediated by TGF-b/Smad pathway. Finally, we have described that RhoA inhibition is a
common intracellular mechanisms involved in statins effects. The in vivo relevance of these findings was assessed in an
experimental model of atherosclerosis in apolipoprotein E deficient mice: Treatment with Atorvastatin increased Smad3
phosphorylation and TRII overexpression, associated to elevated ECM deposition in the VSMCs within atheroma plaques,
while apoptosis was not detected.
Conclusions: Statins enhance TGF-b/Smad pathway, regulating ligand levels, receptor, main signaling pathway and cellular
responses of VSMC, including apoptosis and ECM accumulation. Our findings show that TGF-b/Smad pathway is essential
for statins-dependent actions in VSMCs.
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Introduction
The 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase
inhibitors, also known as statins, have been largely reported as very
useful drugs in atherosclerosis [1,2]. They were initially used to
treat atherosclerosis because their cholesterol-lowering effects.
Nevertheless, multiple pleiotropic beneficial effects have been
observed [2]. Statins regulate a huge amount of cellular responses,
through the blockade of isoprenoids production and inhibition
intracellular signaling systems, including transcription factors, such
as nuclear factor-kB (NF-kB), and kinases, like mitogen-activated
protein kinases (MAPK) cascade and RhoA/ROCK pathway [3].
Transforming growth factor-b (TGF-b) is a pleiotropic cytokine
involved in many human diseases, including cardiovascular disease.
TGF-b acts through binding to specific receptors [4,5], TGF-b
receptor type I (TRI), also known as activin-like kinase (ALK), and
TGF-b receptor type II (TRII), which are serine/threonine kinases.
TRII recruits TGF-b, enabling dimerization with TRI, which
transmits TGF-b signaling into the cell [4,5]. VSMCs present
different TGF-b receptor expression profiles in atherosclerotic
lesions compared with the normal vessel wall [6]. In normal vessels,
TRII is the most abundant receptor. TGF-b through this receptor
increases contractile protein expression. In diseased vessels,however,
cells dominantly express TRI, as a result of which TGF-b could
promote early fatty-streak lesion formation [6]. TGF-b predomi-
nantly transmits the signals through cytoplasmic proteins called
Smads, which act as transcription factors [4]. In VSMCs, TGF-b1,
via ALK5, increases phosphorylation of Smad2 and Smad3, which
bind to Smad4. This complex translocates into the nucleus, where it
interacts with various transcription factors regulating the expression
of TGF-b-responsive genes [7].
A pro-atherogenic role for TGF-b was suspected because of its
ability to promote fibrosis [4,8] and neointima formation, as
shown in experimental models of balloon-injury in rats [9,10].
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3959Figure 1. HMG-CoA reductase inhibition enhances the TGF-b/Smad pathway in VSMCs. Serum starved VSMCs were incubated for 48h
with several concentrations (10
24 to 10
27 mol/L) of Simvastatin (SV) (a) or Atorvastatin (ATV) (b). Then, 1 ng/mL TGF-b was added in fresh medium
and phosphorylation of Smad2/3 was determined after 20 min of incubation. Lower panel: representative western blot of phosphorylated-Smad2 (p-
Smad), p-Smad3, or tubulin (loading control). Upper panel: data of relative protein levels of p-Smad2 (white bars) and p-Smad3 (black bars) expressed
as mean6SEM of 4 experiments. Results of p-Smad levels were obtained from densitometric analysis and expressed as ratio p-Smad/tubulin as n-fold
over control. *p,0.05 vs. control #p,0.05 vs. TGF-b. c. VSMCs, grown in serum-free medium, were transfected with a Smad-luc reporter vector for
24h. Then, cells were treated for 24h with Simvastatin (SV) or Y-27632. After that, 1 ng/mL TGF-b was added in fresh medium and Smad-dependent
transcription was measured after 24h of incubation. *p,0.05 vs. control #p,0.05 vs. TGF-b.
doi:10.1371/journal.pone.0003959.g001
Statins Enhance TGF-b/Smad
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atherosclerosis [11]. Studies in experimental models of athero-
sclerosis in mice have shown TGF-b blockade to accelerate plaque
formation and its progression toward an unstable phenotype [12–
14]. TGF-b has protective anti-inflammatory properties due to its
immunomodulating effects on key cells in atherosclerosis,
including endothelial cells, vascular smooth muscle cells (VSMCs),
macrophages, and T cells [11,14].
An interaction between statins and TGF-b has been suggested.
HMG-CoA reductase inhibition increases circulating TGF-b levels
and TGF-b synthesis in monocytes [15]. In cardiomyocytes, statins
increase TRII expression [16], but there are no data in vascular
cells. Recent studies suggests that statin-induced cholesterol
lowering effects could increase TGF-b/Smad pathway in endo-
thelial cells[17,18]. The present study investigates the mechanisms
underlying the interaction between statins and TGF-b, and
examines whether the beneficial effects of statins in atherosclerosis
are attributable to a modulation of the TGF-b/Smad pathway by
cholesterol independent mechanisms, through small GTP-ases
inhibition. We aimed to demonstrate that statins increase the
ability of TGF-b to activate the Smads; being this pathway
essential for statin dependent effects on VSMCs, including
apoptosis and ECM accumulation.
Studies in VSMCs have shown statins to cause apoptosis. This
effect is greater in the presence of Fetal Bovine Serum (FBS) than
under serum-free conditions [19,20]. This apoptotic effect has been
subject of study in the latest years, however the primary
pharmacological mechanism for statin-induced apoptosis still
remains to be completely explained [21]. In the present work we
try to elucidate the underlying mechanisms for this process,
evaluating the involvement of TGF-b/Smad pathway. The cellular
action of statins can be explained by the inhibition of isoprenoids
production, which are intermediate components of the cholesterol
biosynthetic pathway, such as farnesylpyrophosphate (FPP) and
geranylgeranylpyrophosphate (GGPP)[3]. These isoprenoids regu-
late posttranslational modifications of several proteins, including the
small G proteins. In this study we explore how these cellular action
regulate TGF-b induced VSMC apoptosis
Results
Statins enhance the Smad pathway in cultured vascular
smooth muscle cells
In cultured VSMC, TGF-b induces a rapid activation of Smad
pathway, characterized by increased phosphorylation of the
regulatory Smads (Smad2/3) after 20 min, binding to Smad4 and
nucleartranslocation of the complex [4].The preincubation for48 h
with two statins, simvastatin or atorvastatin, before stimulation with
TGF-b for 20 min, significantly increased TGF-b-induced Smad2
and Smad3 phosphorylation in a dose-dependent manner (Figure 1a
Figure 2. TGF-b mediates statins-induced VSMC apoptosis in 10% FBS. a. VSMCs were incubated with heat inactivated 10% FBS media or
with 10% TGF-b-free FBS. Cells were treated with 10
24 Mol/L of Simvastatin (SV) or atorvastatin (ATV) for 48h. Some cells were preincubated for 1h
with 10
25 Mol/L of the TGF-b type I receptor ALK5 inhibitor (ALK5i) before simvastatin or atorvastatin treatment. Black bars represent FBS treated
cells; striped bars, cells in TGF-b-free FBS. *p,0.05 vs. control. m p,0.05 vs. TFS. b. TGF-b increases statin-induced VSMC apoptosis. VSMCs
were incubated with 10% FBS media. Cells were treated with 10
24 Mol/L of Simvastatin (SV) or atorvastatin (ATV) for 48h, some cells were stimulated
with 10ng/mL of TGF-b.* p ,0.05 vs. control. ¥ p,0.05 vs. 10
24 Mol/L SV. c. TGF-b increases statin-induced VSMC apoptosis in serum-free
medium. Serum starved cells were treated with 10
24 Mol/L of either Simvastatin (SV) or Atorvastatin (ATV) alone or in combination with 1ng/ml TGF-
b for 48h in serum-free conditions. *p,0.05 vs. control. ¥ p,0.05 vs. 10
24 Mol/L SV. $ p,0.05 vs. 10
24 Mol/L SV+TGF-b. d. Smad pathway is
involved in Simvastatin induced cell death. Cells grown in 10%FBS were transfected with either control PC-DNA3B plasmid, or with a Smad7
overexpressing vector for 24h. Then cells were treated for 48h with 10
24 mol/L Simvastatin. Figure a shows percentage of hypodiploid cells
expressed as mean6SEM of 6 experiments. *p,0.05 vs. control &p,0.05 vs. pc-DNA3B transfected cells.
doi:10.1371/journal.pone.0003959.g002
Statins Enhance TGF-b/Smad
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was evaluated using a luciferase-based reporter vector. Pretreatment
with simvastatin also increased Smad transcriptional activity in
response to TGF-b (Figure 1c), while Smad protein levels were not
modified (not show).
TGF-b/Smad pathway mediates vascular smooth muscle
cell death induced by statins
Studies in VSMCs have shown statins to cause apoptosis. This
effect is greater in the presence of FBS than under serum-free
conditions [19,20]. We have investigated the involvement of TGF-
b/Smad pathway in this process. First, as FBS contains TGF-b,w e
evaluated whether statin-induced apoptosis is mediated by TGF-b.
VSMCs were incubated under two different conditions: FBS or
TGF-b-free FBS (TFS), obtained by as described in methods.
Treatment with simvastatin or atorvastatin for 48 h in 10% FBS
caused a significant increase in cell death that was higher than in
10% TFS (Figure 2a). In 10% FBS, the blockade of TGF-b action,
using a specific ALK5 inhibitor (ALK5i), significantly diminished
simvastatin-induced VSMC death (Figure 2a). In addition when
cells treated with statins were stimulated with 10ng/mL of TGF-b
exerted a synergistic apoptotic effect (Figure 2b).
Secondly, we investigated the direct effect of TGF-b on statin-
inducedapoptosis inserum-freemedium.Incontrol experiments,we
found the TGF-b content in 10% FBS to be 1 ng/ml (not shown,
evaluated by ELISA). The low rate of VSMC apoptosis induced by
Atorvastatin or Simvastatin in 0% FBS was dramatically increased
when cells were co-incubated with 1ng/ml TGF-b (Figure 2c).
To evaluate the involvement of the Smad pathway in statin-
induced cell death in 10% FBS, cells were transiently transfected
with a Smad7 overexpressing vector that inhibits TGF-b/Smad-
mediated transcriptional effects by interfering with receptor-
mediated activation of R-Smad [5]. Smad7 overexpression
decreased statin-induced cell death compared to cells transfected
with an empty vector (Figure 2d) - suggesting that the Smad
pathway drives statin-induced cell death.
RhoA mediates statin-induced cell death
Several studies suggest that farnesylated proteins, such as Ras,
regulate cell growth. In the presence of 10% FBS, several groups,
including our own, have shown that small G proteins participate in
cellgrowthregulationbystatins[3,19].InVSMCseveralgroupshave
shown that statins inhibited farnesylated proteins[22,23]. We have
observed that FPP only partially restored statin induced apoptosis
both in 10% and 0% FBS (figure 3a and b). These results indicate
that a farnesylated protein can partially inhibit Statin/TGF-b
induced cell death. Treatment with two different farnesyl transferase
inhibitors (FTI-277 or FTS) for 48h did not induce VSMC death in
10%FBS (Figure 3c). These data indicate that farnesylated proteins
are not involved in statin-induced apoptosis, but they could be
involved in VSMC survival. We have observed in VSMCs that
preincubation with L-mevalonate, the direct HMG-CoA reductase
metabolite, or GGPP, completely abolished simvastatin-induced cell
d e a t hi nb o t h1 0 %F B Sa n di nT G F - b-treated cells (Figure 3a and b).
These data confirm the involvement of a geranylgeranylated, but not
a farnesylated protein, in these effects.
We investigated which geranylated protein was involved in the
regulation of apoptosis. VSMCs were transfected with dominant
negative (DN) expression vectors of the main geranylated proteins
Rac-1, Cdc-42 and RhoA. In 10%FBS only DN-Rac-1 and DN-
Figure 3. RhoA mediates Simvastatin/TGF-b-induced VSMC death. VSMCs were incubated in 10%FBS medium (black bars: a) or in serum-free
conditions (white bars: b). Cells were treated with 10
24 mol/L Simvastatin (SV) alone or in combination with 1ng/mL TGF-b for 48h. Some cells were
pretreated for 1h with 5 mg/mL GGPP, or FPP, or 10
24 mol/L mevalonate (MEV) before Simvastatin treatment. *p,0.05 vs. control. ¥ p,0.05 vs. 10
24
Mol/L SV. $ p,0.05 vs. 10
24 Mol/L SV+TGF-b c. Cells grown in 10%FBS were either treated with FTI-277, farnesylthiosalicylic acid (FTS), or transfected
with a control, DN-Rac1, DN-Cdc42 or DN-RhoA expression vectors and apoptosis was assessed 48h later. *p,0.05 vs. control. d. Cells incubated in
serum-free medium were treated with NSC-23766 (50mMol/L) or C3 exoenzyme (10 mg/mL) alone or in combination with 1ng/mL TGF-b for 48h. The
graphs show the percentage of hypodiploidic cells measured by FACS and expressed as mean6SEM of 4 experiments. *p,0.05 vs. control.
doi:10.1371/journal.pone.0003959.g003
Statins Enhance TGF-b/Smad
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further determined which GTPase was responsible for the
synergistic effect observed with TGF-b/statins. Under serum-free
conditions, cells were treated for 48 h with either NSC-23766, a
selective inhibitor of Rac1-GEF interaction[24], or with C3
exoenzyme from Clostridium botulinum, which inhibits Rho GTPase
activity [25]. Rho inactivation increased TGF-b-mediated apo-
ptosis, while blockade of Rac-1 increased apoptosis independently
of TGF-b (Figure 3d). This might explain the apoptosis observed
with statin treatment alone under serum-free conditions.
We have further evaluated whether Smad pathway could
regulate RhoA-mediated apoptosis. Cotransfection with DN-
RhoA and Smad7 markedly suppressed DN-RhoA-induced cell
death (Figure 4a and b).
RhoA/ROCK pathway mediates statin-dependent
enhancement of Smad activation
We have found that apoptotic effects of statins are driven
through inhibition of the small G proteins Rac-1 and RhoA. We
decided to explore their role on Smad pathway activation by
statins. In VSMCs, incubation with L-mevalonate significantly
decreased the effect of statins on TGF-b-induced Smad transcrip-
tional activation, showing the involvement of the direct inhibition
of HMG-CoA reductase (Figure 5a). GGPP, but not FPP,
inhibited statin-induced Smad enhancement (Figure 5a), suggest-
ing that geranylgeranylated proteins participate in Smad regula-
tion. VSMCs were pretreated for 48 h with either C3 or NSC-
23766. RhoA blockade increased Smad3 phosphorylation induced
by TGF-b (Figure 5b), whereas Rac-1 inhibition did not increase
Figure 4. Smad7 inhibits DN-RhoA induced apoptosis. Cells grown in 10%FBS were transfected with a GFP overexpressing vector or with a
vector that overexpresses DN-RhoA fused to GFP (N19-RhoA-GFP). Some cells were cotransfected with a Smad7 overexpressing vector. After 48h of
transfection apoptosis was evaluated. Figure a shows representative cells (confocal microscopy). Cells were fixed and stained with propidum iodide
and mounted in mowiol. Apoptotic nuclei are bright, condensed and present nuclear bodies in the cytoplasm (arrows) and transfected cells appear in
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ment with Y-27632, an inhibitor of the downstream RhoA
mediator ROCK, enhanced Smad-dependent transcription and
Smad3 phosphorylation caused by TGF-b (Figure 5b).
Statins increase TGF-b receptor type II (TRII) and TGF-b
expression in cultured vascular smooth muscle cells
We further investigated the effect of statins on TGF-b pathway
evaluating its receptor and ligand levels. In VSMCs, incubation
with simvastatin or atorvastatin for 48 h significantly increased
TRII protein expression and TGF-b secretion in a dose-dependent
manner (Figure 6a and b). The upregulation of TRII and TGF-b
caused by statins was reversed by pretreatment with either
mevalonate or GGPP, but not with FPP (Figure 6a and b). The
involvement of the RhoA/ROCK pathway in these processes was
also evaluated. Incubation for 48 h with geranylgeranyl transferase
inhibitor GGTI-286, but not with farnesyl transferase inhibitor
FTI-277 increased TRII protein levels, mimicking the effects of
statins (Figure 6c). Inhibition of RhoA and ROCK by C3 and Y-
27632, respectively, increased TRII and TGF-b production
(Figure 6b and c) in VSMCs, while inhibition of Rac-1 by NSC-
23766 decreased TRII levels (Figure 6c).
Statins enhance the expression of TGF-b dependent ECM
regulatory proteins
TGF-b is one of the main profibrotic factors involved in matrix
regulation in different cell types and pathological settings. In
VSMCs TGF-b, via Smad pathway, regulates ECM-related
proteins, including the profibrotic mediator CTGF [4,26], the
inhibitor of ECM degradation, PAI-1, [27], and the main ECM
component Type I Collagen (Col-1) [4]. We have found that in
VSMCs atorvastatin and simvastatin enhanced TGF-b-dependent
CTGF and PAI-1 upregulation in a dose-dependent manner
(Figure 7a). Statins also increased the ability of TGF-b to induce
Col-1 secretion (Figure 7b).
In the absence of exogenous TGF-b, statins at the doses of 10
24
and 10
25Mol/L strongly increased CTGF production. We further
investigated whether TGF-b is the mediator of statin-induced
CTGF overexpression. The blockade of TGF-b with ALK5i or
TGF-b neutralizing antibody completely inhibited CTGF pro-
Figure 5. RhoA/ROCK inhibition increases the TGF-b/Smad pathway. a. VSMCs, grown in serum-free medium, were transfected with a Smad-
luc reporter vector for 24h. Then, cells were treated for 24h with Simvastatin (SV) or Y-27632. After that, 1 ng/mL TGF-b was added in fresh medium
and Smad-dependent transcription was measured after 24h of incubation. Some cells were pretreated for 1h with 5 mg/mL FPP or GGPP or 10
24 mol/
L mevalonate (Mev) before Simvastatin treatment. Luciferase activity is expressed as mean6SEM of 4 experiments. *p,0.05 vs. control. ¥ p,0.05 vs.
SV 10
24 Mol/L. b: Serum starved VSMCs were incubated for 48h with C3 exoenzyme (10 mg/mL), NSC-23766 (50mMol/L) or Y-27632 (10
25 mol/L),
before stimulation with TGF-b for 20 min. Representative western blot and relative protein levels expressed as mean6SEM of 4 experiments. *p,0.05
vs. control. # p,0.05 vs. TGF-b.
doi:10.1371/journal.pone.0003959.g005
Statins Enhance TGF-b/Smad
PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e3959duction (Figure 8a and b), indicating that endogenous synthesis of
TGF-b by statins regulates CTGF overproduction.
Atorvastatin upregulates TRII and Smad pathway in vivo
The in vivo relevance of these findings was assessed in an
experimental model of atherosclerosis in the apolipoprotein E
deficient (ApoE-/-) mice. Treatment with Atorvastatin at moder-
ate dose (5mg/kg/day) ameliorated experimental atherosclerosis,
reducing lesion areas of atheroma plaques (Figure 9), as observed
in response to statins by many authors. In atherosclerotic lesions
atorvastatin increased Smad3 phosphorylation and TRII expres-
sion compared to non-treated mice. In serial sections, correlation
with Smooth Muscle Actin (SMA) immunostaining was observed,
suggesting that TGF-b/Smad pathway is upregulated in VSMCs
(Figure 10a–c and f). Increased collagen content has been related
to atherosclerotic plaque stabilization [28]. Atorvastatin increased
PAI-1 and Col-1 staining in the fibrous cap correlating with SMA
positive cells (Figure 10d–f). Previous studies have failed to detect
in vivo apoptosis in the atheroma plaques [21]. In ApoE-/- mice we
have not found apoptosis neither in controls nor in atorvastatin-
treated plaques, assessed by immunohistochemistry of cleaved
caspase 3 (not shown). These data indicate that Atorvastatin in
vivo potentiates Smad pathway in VSMCs leading to elevated
ECM protein deposition and amelioration of atherosclerosis,
suggesting a novel mechanism of statins involved in plaque
stability.
Figure 6. Statins upregulates TGF-b receptor type II (TRII) (a) and TGF-b synthesis in VSMCs (b). Serum starved VSMCs were incubated for
48h with several concentrations (10
24 to 10
27 mol/L) of Simvastatin (SV) or Atorvastatin (ATV). Some cells were pretreated for 1h with 5 mg/mL FPP
or GGPP or 10
24 mol/L mevalonate (MEV) before statin treatment. RhoA/ROCK inhibition increases TRII in VSMCs (c) and TGF-b synthesis in
VSMCs (b). c. Serum starved VSMCs were incubated for 48h with FTI-277 or GGTI-286(10-5 Mol/L), C3 exoenzyme (10 mg/mL), NSC-23766 (50mMol/
L) or Y-27632 (10-5 to 10-7 mol/L). Figures a and c show in the lower panel representative western blot of TRII expression and in the upper panel
relative TRII protein levels expressed as mean6SEM of 4 experiments. Figure b shows TGF-b content measured in conditioned media by ELISA. Data
are expressed as mean6SEM of n-fold of increase vs unstimulated cells from 4 experiments. *p,0.05 vs. control. ¥ p,0.05 vs. SV 10-4 Mol/L.
doi:10.1371/journal.pone.0003959.g006
Statins Enhance TGF-b/Smad
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In the present work we report that statins enhance Smad pathway
activation by TGF-b. In addition, statins also induced TRII
upregulation and increased TGF-b synthesis in VSMCs, causing
an amplification of TGF-b-dependent actions. In this sense, statins
render VSMCs more susceptible to TGF-b induced apoptosis, and
increase TGF-b dependent ECM proteins production.
The Smad pathway is the main signaling system for TGF-b.W e
have observed that two statins, simvastatin and atorvastatin increased
the activation of Smad pathway caused by TGF-b. In VSMCs statins
enhanced TGF-b-induced Smad2 and Smad3 phosphorylation and
Smad-dependent gene transcription. The Smads interact with
transcription factors at the promoters of some genes and regulate
their transcription [5]. TGF-b through Smad activation pathway
regulates many cellular responses, including cell growth, cell survival,
cell differentiation and ECM accumulation [5]. Many studies have
demonstrated that statins exert beneficial effects in atherosclerosis.
These drugs inhibit multiple intracellular pathways, including NF-
kB, the MAPK cascade and RhoA/ROCK signaling - all of them
actively involved in the inflammatory process found in aterosclerosis
[3]. We have found that statins enhanced the TGF-b/Smad
pathway, which is essential for TGF-b-mediated cellular responses.
Smad proteins are nuclear factors that depend on the cellular
context to produce their responses [4,5,8]. Since statins exert a
protective role in atherosclerosis, our data indicate that statins
could prepare the cellular context for a protective effect of Smad
proteins. In cultured VSMCs we have found that statins increased
TGF-b induced apoptosis and ECM production, both process
mediated by Smad activation. To find the in vivo relevance of these
Figure 7. Statins enhance TGF-b dependent ECM regulatory proteins upregulation In VSMCs. a. Serum starved VSMCs were
preincubated for 48h with several concentrations (10
24 to 10
27 mol/L) of Simvastatin (SV) or Atorvastatin (ATV), and then stimulated with 1 ng/mL
TGF-b for 24h. These cells were compared with those treated with TGF-b in the absence of statin pretreatment. Figure a shows in the upper panel
representative western blot and in the lower panel relative CTGF and PAI-1 protein levels expressed as mean6SEM of 4 experiments. *p,0.05 vs.
control. # p,0.05 vs. TGF-b. b. Statins increase Col-1 secretion induced by TGF-b. Serum starved VSMCs were preincubated for 24h with
several concentrations (10
25 to 10
27 mol/L) of Simvastatin (SV) or Atorvastatin (ATV), and then stimulated with 1 ng/mL TGF-b for additional 72h.
Conditioned media were analyzed for its Col-1 content by western blot. Figure shows in the lower panel a representative western blot and in the
upper panel media the mean6SEM of 4 experiments. *p,0.05 vs. control. # p,0.05 vs. TGF-b.
doi:10.1371/journal.pone.0003959.g007
Statins Enhance TGF-b/Smad
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model of atherosclerosis that has been widely reported to be
representative (the ApoE-/- mice model). Atorvastatin increased
Smad3 phosphorylation associated to elevated PAI-1 expression,
collagen deposition and SMA staining, indicating that the TGF-b/
Smad pathway is upregulated in VSMCs within the atheroma
plaque and contributes to a more fibrous plaque. In contrast, as
discussed later, we failed to detect apoptosis in vivo. Our data in
cultured VSMCs show that statins upregulate the profibrotic
mediator CTGF, the inhibitor of ECM degradation PAI-1, and
collagen production, all of them regulated by Smads [7,29,30].
Given that cholesterol has been described to inhibit TGF-b/Smad
pathway [17,18] and that Atorvastatin reduced cholesterol levels,
this effect could be attributable to a cholesterol reduction.
However as the cholesterol levels remained elevated compared
to normal levels (62 fold, data not shown) and as our in vitro results
suggest that statin effects are not dependant on cholesterol
reduction, it is reasonable to espaculate that in vivo effect
atorvastatin is likely to be through an inhibition of small GTP-ases.
In atherosclerosis, TGF-b has been considered as a ‘‘protective
cytokine’’, since it plays an important role in maintaining normal
vessel wall structure and controls the balance between inflamma-
tion and ECM deposition [13], and prevents plaque rupture as
shown in human plaques [28]. The loss of this protective effect,
attributed to changes in TGF-b receptor profiles, and modulated
by local TGF-b levels, contributes to the development of
atherosclerosis [31]. We have observed that statins, both in vivo
and in vitro increases TRII expression. Differential TGF-b
receptors expression in VSMCs from normal vessels and
atherosclerotic plaques has been reported [6,31]. Atherosclerotic
plaque-derived cells show almost no TRII expression compared to
cells derived from normal vessels - indicating a VSMC phenotype
change during atherosclerosis [6,31]. The observed upregulation
of TRII expression in cultured VSMCs suggests that statins could
induce phenotype reversion from injured VSMCs to a normal
phenotype, showing a potential mechanisms that explain their
beneficial effects. We have also found that statins increase TGF-b
synthesis in VSMCs. This local production of TGF-b could
participate in the beneficial effects of statins. In experimental
models, the lack of TGF-b signaling promotes the development of
atherosclerotic lesions and unstable plaques [12–14]. In human
carotid artery plaques, a greater expression of TGF-b in
asymptomatic compared to symptomatic lesions has been reported
[28]. TGF-b was mainly expressed in the plaque shoulder and was
associated with a comparative increase in plaque procollagen and
collagen content – thus suggesting that TGF-b may play an
important role in the process of plaque stabilization. All these data
suggest that statins may increase plaque stability, by increasing
collagen content, through TGF-b/Smad pathway enhancement.
Pleiotropics effects of statins have been described in different cell
types and pathological conditions. In this sense, RhoA inhibition
by statins is responsible for many cellular responses induced by
multiple stimuli [3]. However, our findings can not be extrapo-
lated to other pathologies, cells or stimuli. Recently, in a model of
cardiac damage induced by Angiotensin II (AngII) infusion,
pitavastatin down-regulate Smad signaling pathway and cardiac
hypertrophy [32]. In cultured cardiomiocytes statins increase
TRII expression [16] indicating that there must be a different
Figure 8. Endogenous TGF-b is involved in Statin-induced CTGF expression. Serum starved VSMCs were preincubated for 72h with highest
concentrations of statins a. Some cells were preincubated for 1 h with 10
25 mol/L of ALK5i (a)o r1 0mg/mL of TGF-b neutralizing antibody (a-TGF-b)
(b). Figure shows a representative western blot in the lower panel and in the upper panel the mean6SEM of 4 experiments. *p,0.05 vs. control. ¥
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We have also observed that atorvastatin ameliorates vascular
fibrosis caused by AngII, by a process regulated by RhoA and
MAPK activation [33]. Importantly, AngII activates the Smad
pathway independently of TGF-b, and regulated by MAPKs, in
several cultured cells, including VSMCs [7,34], and in vivo [35]. It
has recently been reported that a PPARc agonist exert beneficial
effects on atheroslcerosis in LDL receptor related protein 1 (LRP1)
deficient mice by inhibition of Smad, while TGF-b was reduced
[36]. This indicates that probably Smad pathway is activated by a
TGF-b independent mechanism. Since statins have been reported
to be PPAR agonist [37] it is quite clear that there must be a
different regulation between both models. These data suggests that
the regulation of this pathway is very complex and depends on the
cell type and stimuli studied.
Atherosclerosis is a very complex process that comprises
endothelial dysfunction, inflammation, matrix alterations and
neointima formation. One of the key steps, probably involved in
the origin of atherosclerosis, is VSMC proliferation. Some
therapeutic strategies have focused on inhibiting VSMC prolifera-
tion[38].Ourinvitroexperimentsshowthatundergrowth-arresting
conditions, statins render VSMCs more susceptible to TGF-b
induced apoptosis. Many studies have shown that in VSMCs, statins
induce apoptosis in the presence of 10% FBS, via the inhibition of
small G proteins [19,20]. This was used as an evidence that statins
could increase only proliferative VSMC apoptosis [21]. Our
experiments blocking TGF-b action (in TFS and via a specific
ALK5 inhibitor) showed TGF-b present in serum to be partly
responsible for statin-induced cell death. Moreover, the blockade of
Smad activation by Smad7 overexpression diminished statin-
induced VSMC apoptosis. These data show VSMC apoptosis
caused by statins in the presence of FBS to be mediated by the TGF-
b/Smad pathway and the proliferative state is not responsible for
that apoptosis. Though statins induce apoptosis in cultured VSMCs
as shown here, there are no data showing that statins induce
apoptosis in experimental atherosclerosis. It has been suggested that
induction of VSMC apoptosis is beneficial to treat atherosclerosis
[38]. However, concerns were recently raised that a high rate of
VSMC apoptosis induced by diphtheria toxin may be deleterious
[39]. In their study Clarke et al indicate that apoptosis of VSMC, in
the ApoE-/- mice model of atherosclerosis, increase vascular
damage and inflammation, because the high levels of oxidized lipids
inhibit the clearance of apoptotic cellular debris by competition with
the scavenger receptor. However in our model statin treatment
decreases cholesterol levels indicating that clearance of cellular
debris is now available. In addition, statins have demonstrated
beneficial clinical effects that included amelioration of endothelial
dysfunction, inflammation and increased plaque stability [3] [2].
The Clarke’s study also shows that huge apoptosis of VSMCs during
atherosclerosis development increase instability because the fibrous
cap is thinner [40]. In our model atorvastatin increases ECM
accumulation what leads to a strengthening of the fibrous cap, while
apoptosis was not detectable. Accordingly, it has not been reported
that statin increases apoptosis in vivo in any animal models of
atherosclerosis. This might be because the dose used for animal
models is much lower than the one used in vitro for apoptotic
experiments (around 100 times bigger). It could also occur that the
most of the apoptosis happens in the early phases of atherosclerosis
being highly difficult to detect it. However the in vivo contribution of
apoptosis to atherosclerosis is beyond the scope of the present work
which aimed to determine TGF-b/Smad as an essential pathway
driving, at least some, of the statin so called ‘‘pleiotropic’’ effects.
We have evaluated whether the RhoA/ROCK pathway
participates in the regulation of TGF-b/Smad pathway caused
by statins. In VSMCs, we have found that preincubation with L-
mevalonate and GGPP markedly diminishes statin-induced Smad
activation and overexpression of TRII and TGF-b, as well as
apoptotic effects. Furthermore, these results can be similarly
reproduced using RhoA/ROCK inhibitors (by DN-RhoA trans-
fection, C3 pretreatment or ROCK inhibition with Y-27632), but
not inhibiting other geranylated GTPases such as Rac1 or Cdc42.
This indicates that interaction with TGF-b/Smad signaling can be
attributed to RhoA/ROCK inhibition.
Statins are among the best pharmacological options for the
treatment of atherosclerosis [1,2,41]. Our study reports for the first
timethat a keyfactorintheiractionsisTGF-b.Thissheds lightupon
statin mechanisms of action. To date, attention has focused on
pleiotropic effects regarding the inhibition of isoprenylation, but in
the present study pleiotropic effects offer a new face. We have shown
that such effects are mediated by TGF-b through its main signaling
pathway, the Smad proteins, via inhibition of the RhoA/ROCK
pathway (Figure 11). This for the first time points to a direct effect of
statins in the TGF-b/Smad pathway, that may explain some of the
pleiotropic effects described for statin mechanisms of action.
Methods
Materials
Cell culture reagents (GIBCO), Simvastatin, FTI-277, GGTI-
286, ALK5i, NSC-23766 (Calbiochem), farnesylthiosalicylic acid
(FTS) (alexis), Atorvastatin (generously provided by Pfizer), Y-27632
(TOCRIS Cookson Ltd, Bristol, UK), C3 exoezime, farnesylpyr-
ophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), Me-
valonate (Sigma-Aldrich) and TGF-b (Peprotech) were used.
Figure 9. Atorvastatin treatment retards atherosclerosis de-
velopment. Aortic root samples were stained using Masson tricrome.
Lesion areas were measured from the intima to the lumen. Areas were
determined using Image Pro-Plus software. Figure shows representative
photographs from each group of 8 animals at magnifications of 406
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Briefly, decomplemented FBS was incubated with 1 mg/ml of a
pan-specific polyclonal TGF-b antibody (R&D) for 1h at 37uC,
and then TGF-b was removed by immunocomplex precipitation.
TGF-b depletion was determined by ELISA (TGF-b1 immuno-
assay kit from R&D).
Antibodies employed were: phosphorylated Smad3 (p-Smad3;
Abcam for immunohistochemistry, ), pSmad3 kindly donated by Dr.
Leof, Mayo clinic, Baltimore (for western blot), phosphorylated
Smad2 (p-Smad2), CTGF (Torrey Pines Biolabs) 1:500, TRII 1:50,
PAI-1 (Santa Cruz biotechnology) 1:100, type I collagen (Calbio-
chem)1:40,monoclonal anti-a-SMA1:200,tubulin(Sigma-Aldrich),
and secondary peroxidase-linked antibodies (Amersham).
Cell cultures
VSMCs from Spragle-Dawley rat thoracic aorta were obtained
as previously described [42]. Briefly, Spragle-Dawley rats were
obtained from the animal facilities of the Fundacion Jimenez-Dıaz
Figure 10. Atorvastatin increases the TGF-b/Smad signaling in vivo. ApoE-/- mice of 1 month age were feed with hyperlipidemic diet for
2 months and then randomized in two groups: non treated mice and treated with 5mg/kg/day of atorvastatin for 2 months. Animals were sacrificed
and samples were embedded in paraffin. Aortic roots were stained by immunohistochemistry for p-Smad3 (a), TRII (b), Smooth Muscle Actin (SMA) (c),
PAI-1 (d), and Type I Collagen (COL-1) (e). Figure shows a representative mouse of each group of 8. magnification 406and 1006. Panel f shows the
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Subcultured VSMCs from passages 2 to 7 were used in the
experiments, showed .99% positive immunostaining against a-
SMA antibody and negative for endothelial markers.
Animal model
Male apolipoprotein E deficient (ApoE-/-) mice were purchased
from Jackson Laboratories (Bar Harbor, ME). At 1 month of age,
mice diet was changed to a hyperlipidemic diet (21.2% fat (0.15%
cholesterol)+16.7% proteins) which was maintained during the
whole study in all groups. Four months later, animals were
randomized into two groups, non-treated group (n=8) and mice-
treated with atorvastatin, at the dose of 5mg/kg/day (n=8). After
2 months mice were sacrificed, and different studies were done.
Atorvastatin was added to hyperlipidemic diet. During the entire
period, the animals had free access to water and food.
Experimental mice were killed under anesthesia. All experimental
procedures were approved by the Animal Care and Use
Committee of our Institution, according to the guidelines for
ethical care of the European Community.
Histology and immunohistochemistry
Tissues were perfused in situ with cold saline followed by removal
and overnight fixation for paraffin-embedding. Serial aortic root
sections of 3 mm were stained with different techniques. Masson
trichrome staining was achieved with Bio-Optica kit (Milan). Lesion
areas were measured from the intima to the lumen. Areas were
determined using Image Pro-Plus 1.0 software. For immunohisto-
chemistry, endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in phosphate buffered saline (PBS) for 30 min-
utes. The nonspecific binding was blocked with 6% goat or rabbit
serum depending on the primary antibody used, in PBS solution for
30 min. Then, slides were incubated with primary antibodies
overnight at 4uC. After a PBS rinse, the slides were developed with
a biotin-labeled secondary antibody (Amersham). Then, ABCom-
plex/HRP (DAKO) was added and sections were stained with 3,39-
diaminobenzidine (DAKO) and counterstained with hematoxylin.
Specificity of the immunostaining was assessed by staining with
nonimmune isotype-matched immunoglobulins.
Protein studies
To quantify protein levels Western blot was done. Cells were
homogenized in lysis buffer [(170 mmol/L Tris HCl , 22% glycerol,
2,2% sodium dodecyl sulfate (SDS) with 0,1 mmol/L phenylmethyl-
sulfonyl fluoride, NaF, dithiothreitol, ortovanadate and a protease
inhibitor cocktail)] and then separated by SDS-polyacrilamide gel
electroforesis. CTGF, PAI-1, TRII and the phosphorylation levels of
Smad2/3 were determined in total protein extracts by Western blot.
50 mg of proteins were loaded in each lane; protein content was
determined by the BCA method (Pierce, Rockford, IL). The efficacy
of protein transfer to the membranes was assessed by Ponceau S
staining (not shown). Results of total protein expression were
obtained from densitometric analysis using the GS-800 Calibrated
Densitometer(QuantityOne,Bio-Rad,Spain)andexpressedasratio
protein/tubulin as n-fold over control. TGF-b content in condi-
tioned-medium was evaluated by ELISA (TGF-b1 immunoassay kit
from R&D).
Transfection, DNA Constructs, and promoter studies
VSMCs, in 6 well-plate, were transient transfected for 18h with
FuGENE (Roche Molecular Biochemicals) and the reporter
expression vectors. Smad-dependent promoter activation was
evaluated by transfection of 1 mg Smad/luc (kindly donated by
Dr. Volgestein, Baltimore) and 0.5 mg TK-renilla as internal
control (Clontech). After a 24-h serum starvation step, cells were
stimulated for 24 h and assayed for luciferase/renilla. The results
are shown as the mean of the experiments of different cell culture
preparations, done by triplicate.
To block Smad pathway activation cells were transfected with
PcDNA3-FLAG-Smad7 expression vector kindly donated by Dr.
Massague ´, Memorial Sloan-Kettrin Cancer Center, New York,
USA. To demonstrate Smad7 transfection efficacy an anti-FLAG
antibody was used (not shown). To inhibit small G-proteins cells
were transfected with GFPc1-N19-RhoA, GFPc1-N19-CDC42,
and GFPc1-N19-Rac1 which encodes a dominant negative of
RhoA fused to GFP, kindly donated by Dr. del Pozo, C.N.I.C,
Madrid, Spain. The efficacy of transfection was visualized by
confocal microscopy.
Cell death and apoptosis
For quantification of cell death, cells were seeded in 12-well
plates. At defined time points, the cells were harvested by pooling
non-adherent cells with adherent cells, which were detached by
gentle trypsinization. Apoptosis was quantified by flow cytometry
assessment (FACS) of DNA content of 10.000 cells. Pooled
attached and detached cells were resuspended in a cell
permeabilization buffer containing: 100 mg/mL propidium iodide,
10 mg/mL RNAse A, 0.05% NP-40 in PBS; incubated at 4uC for
1 h; and analyzed on the Cell Quest software. By permeabilizing
the cells propidium iodide was allowed access to both dead and
live cells. The absolute number of cells with decreased DNA
Figure 11. Model for statin action. Proposed model for statin
interaction with the TGF-b/Smad pathway in atherosclerosis. In normal
conditions TRII and TGF-b expression is regulated by RhoA through
ROCK activation. Hyperactivation of RhoA in pathological condition may
lead to the downregulation of TRII and TGF-b that characterizes
unstable plaques. Statins inhibit prenylation of RhoA, thus increasing
TRII expression and TGF- b release. The TRII upregulation allows TGF-b
present in serum or induced by statins to activate the Smad pathway
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counted.
To assess the typical nuclear changes seen in apoptosis, cells
were fixed and stained with propidium iodide. After fixation
propidium iodide stains both live and dead cells (more intense).
Samples were mounted in Mowiol 40–88 (Sigma) and examined
by a laser scanning confocal microscope (Leika).
Statistical analysis
The autoradiographs were scanned using the GS-800 Calibrat-
ed Densitometer (Quantity One, Bio-Rad, Spain). Immunohisto-
chemistry was analized by Metamorph, vesion 6.3r7. Significance
was established with SPSS 11.0 software using Tukey, LSD and
Bonferroni tests. Differences were considered significant when
p,0.05.
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